Sam Chun Dang Pharm Co., Ltd. Quality Score
000250.XKRX
Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Valuation
Growth
Above 30x, priced for sustained outperformance
Negative FCF, no valuation support
Above 10% CAGR, strong compounder
FCF negative, burning cash after capex
Business Quality & Capital Allocation
Heavy dilution above 5%
Modest contraction, within normal range
Net cash position, no leverage concern
Below 8%, may not cover cost of capital
Sam Chun Dang Pharm Co. (000250.XKRX) quality: score, margins and returns
Sam Chun Dang Pharm Co. (000250.XKRX) scores 32/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 7 metrics each scored 0 to 100, on 6.8% operating margins and 2.0% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.
Frequently asked
Is Sam Chun Dang Pharm Co. (000250.XKRX) a high-quality business?+
Sam Chun Dang Pharm Co. scores 32 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a 6.8% operating margin and a 2.0% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does Sam Chun Dang Pharm Co.'s quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from 000250.XKRX's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Sam Chun Dang Pharm Co. scores well and where it falls behind.
What is Sam Chun Dang Pharm Co.'s return on invested capital (ROIC)?+
Sam Chun Dang Pharm Co. earns about 2.0% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to 000250.XKRX's margins and growth on this scorecard to judge durability.
How profitable is Sam Chun Dang Pharm Co.?+
Sam Chun Dang Pharm Co. runs an operating margin of about 6.8% and a net margin of about 9.8%. Revenue has grown at roughly 8.5% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.
Held by ETFs
000250.XKRX is in 12 US ETFs. The largest of them, with 000250.XKRX's weight in each:
iShares Core MSCI Emerging Markets ETFIEMG0.02%of the fund
State Street SPDR Portfolio Developed World ex-US ETFSPDW0.02%of the fund
Vanguard FTSE All-World ex-US Small-Cap Index FundVSS0.05%of the fund
Vanguard FTSE Pacific ETFVPL0.01%of the fund
Schwab International Small-Cap Equity ETFSCHC0.08%of the fund
WisdomTree Emerging Markets ex-State-Owned Enterprises FundXSOE0.02%of the fund
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing 000250.XKRX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.